This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Ticker(s): JNJWho's the expert?
Institution: Southeast Dermatology
- Private practice dermatologist who sees 20 patients a month with low risk basal cell carcinoma
- Specializes in surgical dermatology
- Sees patients for dermatitis, eczema, basal cell carcinoma, acne and psoriasis
Interview GoalTo discuss the standard of care and the potential of JNJ-2113, an oral interleukin-23 receptor (IL-23R) antagonist peptide being developed by Johnson & Johnson.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
